HC Wainwright Comments on Immunocore FY2029 Earnings

Immunocore Holdings plc (NASDAQ:IMCR) – Stock analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Immunocore in a research report issued to clients and investors on Monday, January 27th. HC Wainwright analyst P. Trucchio expects that the company will post earnings of $7.53 per share for the year. HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share.

Several other research firms have also commented on IMCR. Mizuho lowered shares of Immunocore from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $72.00 to $38.00 in a report on Monday, November 11th. UBS Group began coverage on shares of Immunocore in a report on Thursday, October 24th. They issued a “sell” rating and a $24.00 price target for the company. Needham & Company LLC restated a “buy” rating and issued a $71.00 price target on shares of Immunocore in a report on Friday, January 10th. Guggenheim lowered shares of Immunocore from a “buy” rating to a “neutral” rating in a report on Monday, October 7th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $35.00 price target (down previously from $74.00) on shares of Immunocore in a report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $65.64.

Immunocore Price Performance

Immunocore stock opened at $31.64 on Tuesday. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of -33.30 and a beta of 0.76. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore has a 1 year low of $27.69 and a 1 year high of $76.98. The firm has a 50-day moving average of $30.53 and a two-hundred day moving average of $33.22.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.50. The company had revenue of $80.25 million during the quarter, compared to analysts’ expectations of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The firm’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.59) EPS.

Institutional Trading of Immunocore

Several large investors have recently bought and sold shares of IMCR. Primecap Management Co. CA boosted its holdings in shares of Immunocore by 26.7% in the 3rd quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock valued at $76,954,000 after acquiring an additional 520,950 shares during the last quarter. State Street Corp boosted its holdings in shares of Immunocore by 63.9% in the 3rd quarter. State Street Corp now owns 76,671 shares of the company’s stock valued at $2,387,000 after acquiring an additional 29,897 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Immunocore by 25.0% in the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock valued at $17,007,000 after acquiring an additional 109,206 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Immunocore by 125.4% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company’s stock valued at $1,463,000 after acquiring an additional 27,598 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Immunocore by 7,437.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,257 shares of the company’s stock valued at $2,872,000 after acquiring an additional 91,033 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.